valproic acid has been researched along with ADDH in 60 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This case report describes two children who developed hyperammonemia together with frank manic behavior during treatment with a combination of valproic acid and risperidone." | 7.74 | Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. ( Caplan, R; Carlson, T; Reynolds, CA, 2007) |
| " In the dosage used, l-tryptophan was tolerated well by these children, and seizure frequency, as a whole, remained unaltered." | 6.65 | l-Tryptophan in hyperactive child syndrome associated with epilepsy: a controlled study. ( Ghose, K, 1983) |
| "TEAM was a multi-site, 8-week, randomized clinical trial of risperidone, lithium, or divalproex in 279 medication-naïve patients, aged 6 through 15 years, with a DSM-IV diagnosis of bipolar disorder currently in manic or mixed phase." | 5.16 | Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study. ( Axelson, DA; Birmaher, B; Emslie, G; Joshi, P; Luby, J; Riddle, MA; Robb, A; Ryan, ND; Tillman, R; Vitiello, B; Wagner, KD; Walkup, JT; Yenokyan, G, 2012) |
| "Findings from this explorative study strengthen the evidence for the warning against the use of valproate in pregnancy and raise concern of risks of specific psychiatric disorders associated with topiramate and levetiracetam." | 4.31 | Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. ( Alvestad, S; Bjørk, MH; Christensen, J; Cohen, JM; Dreier, JW; Furu, K; Gissler, M; Igland, J; Leinonen, MK; Sun, Y; Tomson, T; Zoega, H, 2023) |
| " In this study, we examined behavioral and hippocampal neurogenesis alterations in male offspring of rats exposed to valproic acid (VPA) during pregnancy." | 3.91 | Prenatal exposure to valproic acid is associated with altered neurocognitive function and neurogenesis in the dentate gyrus of male offspring rats. ( Arai, H; Bolati, K; Fukuhara, T; Ito, M; Kinjo, T; Seki, T; Suzuki, T, 2019) |
| "This case report describes two children who developed hyperammonemia together with frank manic behavior during treatment with a combination of valproic acid and risperidone." | 3.74 | Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. ( Caplan, R; Carlson, T; Reynolds, CA, 2007) |
| "Medical records were reviewed for 42 patients (ages 12-19 years) who were hospitalized for acute mania and discharged with a diagnosis of DSM-III-R or DSM-IV bipolar disorder on either lithium (N = 29) or divalproex sodium (N = 13) treatment." | 3.72 | Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania. ( Altshuler, LL; DeAntonio, M; Frye, MA; Hwang, S; Mintz, J; State, RC; Strober, M, 2004) |
| " We report two cases of an adverse effect of dyskinesia and bruxism when MPH was given to children maintained on valproic acid." | 3.70 | Adverse response to methylphenidate in combination with valproic acid. ( Gara, L; Roberts, W, 2000) |
| "We report on three cases of acutely manic prepubertal children diagnosed with bipolar disorder who were treated with olanzapine in addition to their existing mood stabilizer regimens." | 3.70 | Mood stabilizer augmentation with olanzapine in acutely manic children. ( Chang, KD; Ketter, TA, 2000) |
| "Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study); https://www." | 3.01 | Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization. ( Bailey, BY; Blader, JC; Carlson, GA; Crowell, JA; Daviss, WB; Foley, CA; Kafantaris, V; Margulies, DM; Matthews, TL; Pliszka, SR; Sauder, C; Sinha, C, 2021) |
| " Children whose aggressive behavior persisted at the conclusion of the lead-in phase were randomly assigned to receive double-blind, flexibly dosed divalproex or a placebo adjunctive to stimulant for 8 weeks." | 2.74 | Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. ( Blader, JC; Jensen, PS; Kafantaris, V; Pliszka, SR; Schooler, NR, 2009) |
| " The mechanism of this proposed interaction may involve drug-drug competition at the level of hepatic glucuronidation (conjugation), although shifts in protein binding cannot be ruled out." | 2.69 | Increased plasma valproate concentrations when coadministered with guanfacine. ( Ambrosini, PJ; Sheikh, RM, 1998) |
| " In the dosage used, l-tryptophan was tolerated well by these children, and seizure frequency, as a whole, remained unaltered." | 2.65 | l-Tryptophan in hyperactive child syndrome associated with epilepsy: a controlled study. ( Ghose, K, 1983) |
| "For patients with migraine, the pregnancy labeling of VPA will be changed from Category "D" to "X." | 2.50 | Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions. ( Gentile, S, 2014) |
| "Amphetamine salts have been helpful in treating bipolar children with comorbid ADHD, but no data are available on treating comorbid depression in bipolar children." | 2.43 | Recognizing and managing bipolar disorder in children. ( Wozniak, J, 2005) |
| "Its use in pregnancy is associated with increased risks of congenital malformations and adverse neurodevelopment in the offspring and may be associated with an increased risk of attention-deficit/hyperactivity disorder (ADHD)." | 1.51 | Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Risk for Attention-Deficit/Hyperactivity Disorder in Offspring. ( Brikell, I; Christensen, J; Dalsgaard, S; Dreier, JW; Pedersen, L; Sun, Y, 2019) |
| "Benign myoclonic epilepsy in infancy (BMEI) is a well-defined electro-clinical syndrome, classically associated with a good prognosis." | 1.40 | [Benign myoclonic epilepsy in infancy: natural history and behavioral and cognitive outcome]. ( Carreras-Sáez, I; Domínguez-Carral, J; Fournier-Del Castillo, MC; García-Peñas, JJ; Jiménez-Echevarría, S; Pérez-Jiménez, MÁ, 2014) |
| "Methylphenidate is a short-acting stimulant." | 1.39 | Methylphenidate-induced acute orofacial and extremity dyskinesia. ( Donmez, A; Isik, B; Orun, E; Sonmez, FM; Tas, T; Yilmaz, AE, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (6.67) | 18.7374 |
| 1990's | 9 (15.00) | 18.2507 |
| 2000's | 22 (36.67) | 29.6817 |
| 2010's | 18 (30.00) | 24.3611 |
| 2020's | 7 (11.67) | 2.80 |
| Authors | Studies |
|---|---|
| Błaszczyk, B | 1 |
| Miziak, B | 1 |
| Pluta, R | 1 |
| Czuczwar, SJ | 1 |
| Dreier, JW | 2 |
| Bjørk, MH | 1 |
| Alvestad, S | 1 |
| Gissler, M | 1 |
| Igland, J | 1 |
| Leinonen, MK | 1 |
| Sun, Y | 2 |
| Zoega, H | 1 |
| Cohen, JM | 1 |
| Furu, K | 1 |
| Tomson, T | 1 |
| Christensen, J | 2 |
| Kinjo, T | 1 |
| Ito, M | 1 |
| Seki, T | 1 |
| Fukuhara, T | 1 |
| Bolati, K | 1 |
| Arai, H | 1 |
| Suzuki, T | 1 |
| Sakade, Y | 1 |
| Yamanaka, K | 1 |
| Soumiya, H | 1 |
| Furukawa, S | 1 |
| Fukumitsu, H | 1 |
| Blader, JC | 2 |
| Pliszka, SR | 2 |
| Kafantaris, V | 2 |
| Foley, CA | 1 |
| Carlson, GA | 1 |
| Crowell, JA | 1 |
| Bailey, BY | 1 |
| Sauder, C | 1 |
| Daviss, WB | 1 |
| Sinha, C | 1 |
| Matthews, TL | 1 |
| Margulies, DM | 1 |
| Cortese, S | 1 |
| Novins, DK | 1 |
| Oh, Y | 1 |
| Joung, YS | 1 |
| Choi, J | 1 |
| Stuver, R | 1 |
| Khanna, P | 1 |
| Wischhusen, JW | 1 |
| Cobb, C | 1 |
| Bockorny, B | 1 |
| Wiggs, KK | 1 |
| Rickert, ME | 1 |
| Sujan, AC | 1 |
| Quinn, PD | 1 |
| Larsson, H | 1 |
| Lichtenstein, P | 1 |
| Oberg, AS | 1 |
| D'Onofrio, BM | 1 |
| Meador, KJ | 1 |
| Pedersen, L | 1 |
| Brikell, I | 1 |
| Dalsgaard, S | 1 |
| Kanemura, H | 1 |
| Sano, F | 1 |
| Tando, T | 1 |
| Hosaka, H | 1 |
| Sugita, K | 1 |
| Aihara, M | 1 |
| Allen, MB | 1 |
| Baker, JC | 1 |
| Nuernberger, JE | 1 |
| Vargo, KK | 1 |
| Santos-Cubiñá, J | 1 |
| Torres-Rodríguez, A | 1 |
| Castaing-Lespier, PA | 1 |
| Sabaté, N | 1 |
| Torres-Martin, A | 1 |
| Carlo, S | 1 |
| Domínguez-Carral, J | 1 |
| García-Peñas, JJ | 1 |
| Pérez-Jiménez, MÁ | 1 |
| Fournier-Del Castillo, MC | 1 |
| Carreras-Sáez, I | 1 |
| Jiménez-Echevarría, S | 1 |
| Gentile, S | 1 |
| Ciftci, S | 1 |
| Guler, A | 1 |
| Deveci, E | 1 |
| Celebisoy, N | 1 |
| Yuceyar, N | 1 |
| Miklowitz, DJ | 1 |
| Chang, KD | 2 |
| Kummer, A | 1 |
| Teixeira, A | 1 |
| Schooler, NR | 1 |
| Jensen, PS | 1 |
| Steiner, H | 2 |
| Karnik, NS | 1 |
| Torrioli, M | 1 |
| Vernacotola, S | 1 |
| Setini, C | 1 |
| Bevilacqua, F | 1 |
| Martinelli, D | 1 |
| Snape, M | 1 |
| Hutchison, JA | 1 |
| Di Raimo, FR | 1 |
| Tabolacci, E | 1 |
| Neri, G | 1 |
| Sahu, JK | 1 |
| Bos, MJ | 1 |
| de Weerd, AW | 1 |
| Hagebeuk, EE | 1 |
| Liu, HY | 1 |
| Potter, MP | 1 |
| Woodworth, KY | 1 |
| Yorks, DM | 1 |
| Petty, CR | 1 |
| Wozniak, JR | 1 |
| Faraone, SV | 1 |
| Biederman, J | 1 |
| Lance, EI | 1 |
| Shapiro, BK | 1 |
| Yilmaz, AE | 1 |
| Donmez, A | 1 |
| Orun, E | 1 |
| Tas, T | 1 |
| Isik, B | 1 |
| Sonmez, FM | 1 |
| Vitiello, B | 1 |
| Riddle, MA | 1 |
| Yenokyan, G | 1 |
| Axelson, DA | 1 |
| Wagner, KD | 1 |
| Joshi, P | 1 |
| Walkup, JT | 1 |
| Luby, J | 1 |
| Birmaher, B | 1 |
| Ryan, ND | 1 |
| Emslie, G | 1 |
| Robb, A | 1 |
| Tillman, R | 1 |
| Levy, T | 1 |
| Bloch, Y | 1 |
| Kowatch, RA | 2 |
| Sethuraman, G | 1 |
| Hume, JH | 1 |
| Kromelis, M | 1 |
| Weinberg, WA | 1 |
| State, RC | 1 |
| Frye, MA | 1 |
| Altshuler, LL | 1 |
| Strober, M | 1 |
| DeAntonio, M | 1 |
| Hwang, S | 1 |
| Mintz, J | 1 |
| Scheffer, RE | 1 |
| Carmody, T | 1 |
| Rush, AJ | 1 |
| Wozniak, J | 1 |
| Kruszewski, SP | 1 |
| Paczynski, R | 1 |
| Mendhekar, DN | 1 |
| Bebarta, VS | 1 |
| Kostic, MA | 1 |
| Gonzalez, MG | 1 |
| Pavuluri, MN | 1 |
| Schenkel, LS | 1 |
| Aryal, S | 1 |
| Harral, EM | 1 |
| Hill, SK | 1 |
| Herbener, ES | 1 |
| Sweeney, JA | 1 |
| Miyazaki, M | 1 |
| Ito, H | 1 |
| Saijo, T | 1 |
| Mori, K | 1 |
| Kagami, S | 1 |
| Kuroda, Y | 1 |
| Kratochvil, CJ | 1 |
| Varley, C | 1 |
| Cummins, TK | 1 |
| Martin, A | 1 |
| Bora, E | 1 |
| Vahip, S | 1 |
| Akdeniz, F | 1 |
| Saxena, K | 1 |
| Howe, M | 1 |
| Simeonova, D | 1 |
| Chang, K | 1 |
| Barzman, DH | 1 |
| DelBello, MP | 1 |
| Adler, CM | 1 |
| Stanford, KE | 1 |
| Strakowski, SM | 1 |
| Carlson, T | 1 |
| Reynolds, CA | 1 |
| Caplan, R | 1 |
| Tahiroglu, AY | 1 |
| Avci, A | 1 |
| Wammanda, RD | 1 |
| Berlin, CM | 1 |
| Ghose, K | 1 |
| Debray-Ritzen, P | 1 |
| Dubois, H | 1 |
| Frank, Y | 1 |
| Donovan, SJ | 1 |
| Susser, ES | 1 |
| Nunes, EV | 1 |
| Stewart, JW | 1 |
| Quitkin, FM | 1 |
| Klein, DF | 1 |
| Brasić, JR | 1 |
| Barnett, JY | 1 |
| Crumley, FE | 1 |
| Steele, M | 1 |
| Fisman, S | 1 |
| Damore, J | 1 |
| Stine, J | 1 |
| Brody, L | 1 |
| Schaller, JL | 1 |
| Behar, D | 1 |
| Ambrosini, PJ | 1 |
| Sheikh, RM | 1 |
| Gara, L | 1 |
| Roberts, W | 1 |
| Ketter, TA | 1 |
| Spiel, W | 1 |
| Schuch, B | 1 |
| Widmer, U | 1 |
| Matthews-Ferrari, K | 1 |
| Karroum, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD[NCT00794625] | Phase 4 | 270 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Family-Focused Therapy as Early Treatment for Youth at Risk for Bipolar Disorder[NCT00943085] | 52 participants (Anticipated) | Interventional | 2007-04-30 | Completed | |||
| Early Intervention for Youth at Risk for Bipolar Disorder[NCT01483391] | 150 participants (Anticipated) | Interventional | 2011-10-06 | Completed | |||
| Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder[NCT00228046] | Phase 4 | 40 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| Treatment of Early Age Mania (TEAM) Study[NCT00057681] | Phase 3 | 379 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Comparison of Omega-3 Fatty Acids vs. Placebo in Children and Adolescents With Bipolar Disorder[NCT00252486] | 65 participants (Actual) | Interventional | 2001-11-30 | Completed | |||
| Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Cross-Over Placebo Controlled Trial[NCT00305370] | Phase 4 | 20 participants (Anticipated) | Interventional | 2005-08-31 | Completed | ||
| A Collaborative Treatment Network for Youth With or at High Risk for Bipolar Disorder[NCT05427123] | 80 participants (Anticipated) | Observational | 2022-07-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Clinical Global Impressions-Bipolar (CGI-BP) assessment instrument measured improvement in mania, depression, and overall bipolar illness. The primary outcome measure was mania improvement, which measured the change in mania from baseline. Scores were 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Medication - Lithium | 2.49 |
| Randomized Medication - Divalproex Sodium | 2.73 |
| Randomized Medication - Risperidone | 1.70 |
The K-SADS Mania Rating Scale (KMRS) is comprised of 15 items modified from WASH-U-KSADS items. The individual items are scored on a 1-6 severity scale and then these item scores are summed to create an overall KMRS score. Guidelines for interpretation are as follows: 0-11 = no or minimal mania, 12-17 = mild mania, 18-25 = moderate mania, 26+ = marked or worse mania. The maximum possible score is 64. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Medication - Lithium | 24.06 |
| Randomized Medication - Divalproex Sodium | 26.31 |
| Randomized Medication - Risperidone | 14.58 |
The Modified Side Effects Form for Children and Adolescents includes 62 potential side effects, with measures of frequency and severity for each item. Frequencies are 0=not present, 1=1-2 days, 2=3-4 days, 3=5-7 days. Severity scores are 0=not present, 1=mild (does not interfere with functioning), 2=moderate (some interference with functioning), 3=severe (functioning is significantly impaired because of side effects). Items for cardiovascular, gastrointestinal, central nervous system, ocular, mouth and nose, genito urinary, dermatology, musculo-skeletal, and other side effects are included. For analyses, side effects that were reported at any frequency and a severity of 2 or greater were considered present. (NCT00057681)
Timeframe: Measured at Week 8
| Intervention | side effects at week 8 (Mean) |
|---|---|
| Randomized Medication - Lithium | 5.11 |
| Randomized Medication - Divalproex Sodium | 4.95 |
| Randomized Medication - Risperidone | 3.70 |
8 reviews available for valproic acid and ADDH
| Article | Year |
|---|---|
Epilepsy in Pregnancy-Management Principles and Focus on Valproate.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autism | 2022 |
Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Bipolar Di | 2014 |
Prevention of bipolar disorder in at-risk children: theoretical assumptions and empirical foundations.
Topics: Adolescent; Adult; Affect; Amygdala; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; | 2008 |
Prevention of bipolar disorder in at-risk children: theoretical assumptions and empirical foundations.
Topics: Adolescent; Adult; Affect; Amygdala; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; | 2008 |
Prevention of bipolar disorder in at-risk children: theoretical assumptions and empirical foundations.
Topics: Adolescent; Adult; Affect; Amygdala; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; | 2008 |
Prevention of bipolar disorder in at-risk children: theoretical assumptions and empirical foundations.
Topics: Adolescent; Adult; Affect; Amygdala; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; | 2008 |
Pharmacologic treatments for pediatric bipolar disorder: a review and meta-analysis.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivi | 2011 |
[Pharmacotherapy for conduct disorder in children and adolescents].
Topics: Adolescent; Aggression; Anticoagulants; Antimanic Agents; Antipsychotic Agents; Attention Deficit Di | 2012 |
Recognizing and managing bipolar disorder in children.
Topics: Adolescent; Age Factors; Amphetamine; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disor | 2005 |
Managing adverse reactions to psychotropic medications.
Topics: Adolescent; Anticonvulsants; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivit | 2005 |
Advances in pediatric pharmacology and toxicology.
Topics: Animals; Anti-Bacterial Agents; Aspirin; Attention Deficit Disorder with Hyperactivity; Biological A | 1983 |
13 trials available for valproic acid and ADDH
| Article | Year |
|---|---|
Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2021 |
Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.
Topics: Adolescent; Aggression; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorders; Atten | 2009 |
Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys.
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child; Female; Fragile X | 2010 |
Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study.
Topics: Adolescent; Age Factors; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Attention Deficit | 2012 |
Combination pharmacotherapy in children and adolescents with bipolar disorder.
Topics: Adolescent; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorde | 2003 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Topics: Adolescent; Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Di | 2005 |
Favorable response of ADHD with giant SEP to extended-release valproate.
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; | 2006 |
Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder.
Topics: Adolescent; Affect; Aggression; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorder | 2006 |
The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s).
Topics: Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Attention Deficit and Disruptive Beh | 2006 |
l-Tryptophan in hyperactive child syndrome associated with epilepsy: a controlled study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Child; Clinical Trials as | 1983 |
Visual event related potentials after methylphenidate and sodium valproate in children with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Electroencephalography; Evoked Potentials, Vis | 1993 |
Divalproex treatment of disruptive adolescents: a report of 10 cases.
Topics: Adolescent; Adolescent Behavior; Aggression; Ambulatory Care; Attention Deficit Disorder with Hypera | 1997 |
Increased plasma valproate concentrations when coadministered with guanfacine.
Topics: Adrenergic alpha-Agonists; Anticonvulsants; Attention Deficit and Disruptive Behavior Disorders; Att | 1998 |
39 other studies available for valproic acid and ADDH
| Article | Year |
|---|---|
Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders.
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Child; Ch | 2023 |
Prenatal exposure to valproic acid is associated with altered neurocognitive function and neurogenesis in the dentate gyrus of male offspring rats.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Behavior, Animal; | 2019 |
Exposure to valproic acid during middle to late-stage corticogenesis induces learning and social behavioral abnormalities with attention deficit/hyperactivity in adult mice.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Cerebral Cortex; Female; M | 2019 |
Editorial: Why JAACAP Published an "Inconclusive" Trial: Optimize, Optimize, Optimize Psychostimulant Treatment.
Topics: Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2021 |
Incidence of Neutropenia with Valproate, Antipsychotics, and ADHD Medication Combination Treatment in Children and Adolescents.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Female; Huma | 2020 |
Isolated severe thrombocytopenia in the setting of extreme hyperthermia.
Topics: Adult; Amphetamine-Related Disorders; Attention Deficit Disorder with Hyperactivity; Blood Platelets | 2020 |
Antiseizure medication use during pregnancy and risk of ASD and ADHD in children.
Topics: Adolescent; Adult; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2020 |
Fetal Valproate Exposure and Attention-Deficit/Hyperactivity Disorder.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Female; Humans; Pregnancy; Prenatal | 2019 |
Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Risk for Attention-Deficit/Hyperactivity Disorder in Offspring.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child; Cohort Studies; Denmark; Epil | 2019 |
EEG improvements with antiepileptic drug treatment can show a high correlation with behavioral recovery in children with ADHD.
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Brain Waves; Child; Elec | 2013 |
Precursor manic behavior in the assessment and treatment of episodic problem behavior for a woman with a dual diagnosis.
Topics: Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Behavioral Sy | 2013 |
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Benzo | 2013 |
[Benign myoclonic epilepsy in infancy: natural history and behavioral and cognitive outcome].
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child Behavior Disorders; Cognition | 2014 |
A case with hyperammonemic encephalopathy triggered by single dose valproate.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Diseases; Female; GABA Agents; Humans; Hyperamm | 2016 |
Methylphenidate in attention deficit hyperactivity disorder and bipolar disorder.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous Sy | 2008 |
Integrated treatment of aggression in the context of ADHD in children refractory to stimulant monotherapy: a window into the future of child psychopharmacology.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2009 |
Valproic acid and ADHD symptoms in fragile X syndrome: more evidence is needed.
Topics: Attention Deficit Disorder with Hyperactivity; Electroencephalography; Female; Fragile X Syndrome; H | 2010 |
[Staring episodes in children with developmental disorders: epilepsy or behaviour?].
Topics: Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Child; Child Behavior; Diagnosis, | 2011 |
Confounding diagnoses in the neurodevelopmental disabilities population: a child with hearing loss, absence epilepsy, and attention-deficit hyperactivity disorder (ADHD).
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Audiometry, Pure-Tone; Central Nervo | 2013 |
Methylphenidate-induced acute orofacial and extremity dyskinesia.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; C | 2013 |
Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania.
Topics: Adolescent; Adult; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; | 2004 |
Conclusions inconsistent with results with amphetamines and divalproex.
Topics: Amphetamines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Cent | 2005 |
Clonidine-induced gynecomastia and hyperprolactinemia in a 6-year-old child.
Topics: Age Factors; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Comor | 2005 |
Neurocognitive function in unmedicated manic and medicated euthymic pediatric bipolar patients.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bi | 2006 |
Less is more: inpatient management of a child with complex pharmacotherapy.
Topics: Aggression; Amphetamines; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Depressio | 2006 |
Sustained attention deficits in manic and euthymic patients with bipolar disorder.
Topics: Adult; Anticonvulsants; Antimanic Agents; Arousal; Attention Deficit Disorder with Hyperactivity; Bi | 2006 |
Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania.
Topics: Antipsychotic Agents; Asperger Syndrome; Attention Deficit Disorder with Hyperactivity; Bipolar Diso | 2007 |
Polypharmacy and EPS in a child; a case report.
Topics: Attention Deficit Disorder with Hyperactivity; Benztropine; Bipolar Disorder; Child; Comorbidity; Do | 2007 |
Hyperactivity and inattention--a successful response to table coffee.
Topics: Attention Deficit Disorder with Hyperactivity; Caffeine; Central Nervous System Stimulants; Child, P | 2007 |
[Simple tic disease in children. A report on 93 cases (author's transl)].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Female; Humans; | 1980 |
Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid.
Topics: Anti-Dyskinesia Agents; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autistic Dis | 1997 |
Valproic acid for Kleine-Levin syndrome.
Topics: Adolescent; Anger; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; | 1997 |
Bipolar disorder in children and adolescents: current challenges.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Clom | 1997 |
Medication-induced hypomania in Asperger's disorder.
Topics: Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Bipolar Disorder | 1998 |
Treatment of a case of comorbid bipolar disorder and attention-deficit/hyperactivity disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Attention Deficit Disorder with H | 1998 |
Adverse response to methylphenidate in combination with valproic acid.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Bruxism; Central Nervous System Stim | 2000 |
Mood stabilizer augmentation with olanzapine in acutely manic children.
Topics: Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzodiazepin | 2000 |
[Therapy with convulex in patients with disorders of concentration and of the visual motor system].
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Psychological | 1979 |
Mania and anticonvulsant therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Epilepsy, Absence; Ethosuxim | 1992 |